Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a note issued to investors on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price objective on shares of Regulus Therapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, April 21st.

Regulus Therapeutics Stock Down 2.9 %

NASDAQ:RGLS opened at $1.33 on Wednesday. The company has a 50 day moving average price of $1.20 and a 200-day moving average price of $1.37. Regulus Therapeutics has a 1-year low of $0.76 and a 1-year high of $3.40.

Regulus Therapeutics (NASDAQ:RGLS – Get Rating) last posted its earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.09. Analysts forecast that Regulus Therapeutics will post -1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Regulus Therapeutics

A number of large investors have recently modified their holdings of the business. Federated Hermes Inc. acquired a new position in Regulus Therapeutics during the first quarter worth about $8,656,000. Vanguard Group Inc. grew its holdings in shares of Regulus Therapeutics by 21.4% in the first quarter. Vanguard Group Inc. now owns 3,678,334 shares of the biopharmaceutical company’s stock valued at $1,096,000 after purchasing an additional 648,121 shares during the period. Renaissance Technologies LLC raised its stake in Regulus Therapeutics by 498.2% during the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 111,100 shares during the period. Northern Trust Corp boosted its holdings in Regulus Therapeutics by 42.9% in the 1st quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 50,518 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new position in Regulus Therapeutics in the 3rd quarter valued at about $54,000. Hedge funds and other institutional investors own 55.47% of the company’s stock.

About Regulus Therapeutics

(Get Rating)

Regulus Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.